Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
1.468 JPY | +0,69% | -0,81% | +3,31% |
Attività
Numero di dipendenti: 350
Vendite per attività
JPY in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Pharmaceutical
100,0
%
| 15 569 | 100,0 % | 12 766 | 100,0 % | -18,00% |
Vendite per regione
JPY in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Japan
48,4
%
| 80 | 0,5 % | 6 173 | 48,4 % | +7.616,25% |
Switzerland
31,4
%
| 2 564 | 16,5 % | 4 004 | 31,4 % | +56,16% |
United States
10,8
%
| 9 934 | 63,8 % | 1 373 | 10,8 % | -86,18% |
Bermuda
9,5
%
| 2 849 | 18,3 % | 1 212 | 9,5 % | -57,46% |
United Kingdom
0,0
%
| 142 | 0,9 % | 4 | 0,0 % | -97,18% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Chris Cargill
CEO | Chief Executive Officer | 40 | 20/09/17 |
Shinichi Tamura
FOU | Founder | 74 | 22/06/90 |
Director of Finance/CFO | - | 24/03/22 | |
Compliance Officer | 70 | 01/04/15 | |
Satoshi Tanaka
PRN | Corporate Officer/Principal | - | 01/07/23 |
Kieran Johnson
AUD | Comptroller/Controller/Auditor | 55 | 24/03/22 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Shinichi Tamura
FOU | Founder | 74 | 22/06/90 |
Noriaki Nagai
BRD | Director/Board Member | 66 | 27/03/19 |
Rolf Soderstrom
BRD | Director/Board Member | 58 | 25/03/20 |
Kuniaki Kaga
BRD | Director/Board Member | 72 | 22/06/18 |
Tomohiro Toyama
BRD | Director/Board Member | 74 | 01/06/11 |
David Roblin
BRD | Director/Board Member | 57 | 22/06/18 |
Chris Cargill
CEO | Chief Executive Officer | 40 | 20/09/17 |
Miwa Seki
BRD | Director/Board Member | 59 | 24/03/22 |
Eiko Tomita
BRD | Director/Board Member | - | - |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 0 | 89 446 777 | 79 495 767 ( 88,87 %) | 335 ( 0,000375 %) | 88,87 % |
Partecipazioni
Nome | Azioni | % | Valorizzazione |
---|---|---|---|
929 353 | 1.03% | 10 501 689 $ | |
BIOHAVEN LTD. 0.03% | 27 308 | 0.03% | 1 493 475 $ |
NXERA PHARMA CO., LTD. 0.00% | 300 | 0.00% | 3 294 $ |
Coordinate società
Sosei Group Corp.
PMO Hanzomon, 11/F 2-1 Koji-machi
102-0083, Tokyo
+81 3 5210 3290
https://soseiheptares.comSocietà del gruppo
Nome | Categoria e settore |
---|---|
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. |
Pharmaceuticals: Major
|
Settore
Vendite per regione
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
+3,31% | 832 Mln | |
-3,45% | 87,17 Mrd | |
+1,97% | 40,1 Mrd | |
+57,67% | 25,12 Mrd | |
-14,82% | 15,59 Mrd | |
-8,82% | 12 Mrd | |
-16,29% | 11,8 Mrd | |
-41,58% | 11,8 Mrd | |
+7,49% | 8,81 Mrd | |
-10,53% | 8,24 Mrd |
- Borsa valori
- Azioni
- Azione 4565
- Società Nxera Pharma Co., Ltd.